• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Moderna Therapeutics Expands Headquarters To Technology Square in Cambridge, Massachusetts

Moderna Therapeutics, a company developing messenger RNA therapeutics, expanded its headquarters and relocated to Technology Square in Cambridge, Massachusetts. With the addition of the new space, the company said it will have up to 100 full-time employees at its two locations by the end of this year.

The new site will be the center of Moderna's R&D and provide a significant increase in laboratory space for formulation, screening, and both in-vivo and in-vitro studies. The facility houses administrative and corporate needs as well as IT specialists. It is equipped with state of the art technology to enable virtual collaboration and cloud-based computing. Moderna's previous Cambridge headquarters will continue to serve as an additional site for manufacturing and quality.

"We are thrilled to expand our presence in Massachusetts, the country's most important hub of biotech innovation, which has been a great source of talent and ideas to Moderna from its earliest days," said Stephane Bancel, President and Founding CEO of Moderna. "With this facility, we intend to deliver on the promise of messenger RNA therapeutics by developing transformative new medicines for a wide range of diseases, including many that are untreatable today."

"In Massachusetts we invest in the life sciences because we are choosing to shape our own future," said Gov. Deval Patrick. "I congratulate Moderna on their new facility and look forward to the jobs and economic opportunities they will bring."

"On behalf of the team at the Massachusetts Life Sciences Center, congratulations to Moderna on its expansion here in the Commonwealth," said MLSC President and CEO Dr. Susan Windham-Bannister. "We are pleased to have awarded Moderna 2011 and 2012 Tax Incentives tied to their new job creation in Massachusetts and look forward to the great R&D efforts in 'messenger RNA Therapeutics' that will be taking place in this new space."

Exclusive Research